The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Equillium, Inc. | COM | 29446K106 | 2,609,717 | 1,824,977 | SH | DFND | 1,824,977 | 0 | 0 | |||
| Ovid Therapeutics, Inc. | COM | 690469101 | 7,475,000 | 5,750,000 | SH | DFND | 5,750,000 | 0 | 0 | |||
| Ovid Therapeutics, Inc. | COM | 690469101 | 2,316,595 | 1,781,996 | SH | SOLE | 1,781,996 | 0 | 0 | |||
| Xilio Therapeutics, Inc. (formerly Akrevia Therapeutics) | COM | 98422T100 | 1,243,084 | 1,475,121 | SH | DFND | 1,475,121 | 0 | 0 | |||
| Shattuck Labs, Inc. | COM | 82024L103 | 1,232,329 | 515,619 | SH | DFND | 515,619 | 0 | 0 | |||
| Lyell Immunopharma, Inc. | COM | 55083R104 | 891,365 | 54,887 | SH | DFND | 54,887 | 0 | 0 | |||
| Rani Therapeutics Holdings, Inc. | COM | 753018100 | 101,554 | 203,190 | SH | DFND | 203,190 | 0 | 0 | |||
| Standard Biotools, Inc. | COM | 34385P108 | 21,470 | 16,515 | SH | DFND | 16,515 | 0 | 0 | |||
| American Well Corporation | COM | 03044L204 | 478,061 | 77,733 | SH | DFND | 77,733 | 0 | 0 | |||